Phytochemicals to prevent inflammation and allergy

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 6, Issue 2, 2012, Pages 147-158

  Bellik, Yuva ^a   Hammoudi, Si M ^b   Abdellah, Fatiha ^b   Iguer Ouada, Mokrane ^a   Boukraâ, Laïd ^b  

^a UNIVERSITY OF BEJAIA   (Algeria)

^b UNIVERSITY OF TIARET   (Algeria)

Author keywords

Anti allergic; Anti inflammatory; Clinical trials; Phytochemicals

Indexed keywords

ACONITINE; ALKALOID; ALPHA TOCOPHEROL; ASCORBIC ACID; BOSWELLIC ACID; CARBOXYLIC ACID DERIVATIVE; EPIGALLOCATECHIN GALLATE; FLAVONE DERIVATIVE; GAMMA LINOLENIC ACID; GENISTEIN; GINGER EXTRACT; GINGEROL; GREEN TEA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE ALKALOID; MATRINE; MORPHINE; OXAZOLIDINE DERIVATIVE; PAPAVERINE; PHENOL DERIVATIVE; PLANT MEDICINAL PRODUCT; RESVERATROL; ROSMARINUS OFFICINALIS EXTRACT; SCUTELLARIA BAICALENSIS EXTRACT; SILYMARIN; TERPENOID; THIAZOLIDINE DERIVATIVE; TURMERIC; UNINDEXED DRUG; VITAMIN K GROUP;

ALLERGY; ALTERNATIVE MEDICINE; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRITIS; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG POTENTIATION; EAR EDEMA; FEVER; HUMAN; INFLAMMATION; MEDICINAL PLANT; NONHUMAN; PATENT; PAW EDEMA; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL AGENTS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; HYPERSENSITIVITY; INFLAMMATION; PATENTS AS TOPIC; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84860276719     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221312800166886     Document Type: Review

References (86)

1. Calixto JB. Efficacy, safety, quality control, marketing and regula- tory guidelines for herbal medicines (phytotherapeutic agents) Braz J Med Biol Res 2000; 33: 179-89.
2. Shu YZ. Recent natural products based drug development: A pharmaceutical industry perspective. J Nat Prod 1998; 61: 1053-71.
3. Rates SMK. Plants as source of drugs. Toxicon 2001; 39: 603-13.
4. Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and development. J Nat Prod 1997; 60: 52-60.
5. Gupta SS. Prospects and perspectives of natural plant products in medicine. Indian J Pharmacol 1994; 26:1-12.
6. Vaidya AB, Antarkar VDS. New drugs from medicinal plants: Opportunities and approaches. J Assoc Phys India 1994; 42: 221-8.
7. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor- kappa B: Its role in health and disease. J Mol Med 2004; 82: 434-48.
8. Aggarwal BB, Takada Y, Shishodia S, Gutierrez AM, Oommen OV, Ichikawa H, et al. Nuclear transcription factor NF-kappa B: Role in biology and medicine. Indian J Exp Biol 2004: 42; 341-53.
9. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
10. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
11. Kim YS, Young MR, Bobe G, Colburn NH, Milner JA. Bioactive food components, inflammatory targets, and cancer prevention. Cancer Prev Res 2009; 2: 200-8.
12. Arya V, Arya ML. A Review on anti-inflammatory plant barks. Int J PharmTech Res 2011; 3: 899-908.
13. Menon, G. R., Fast, D. J., Krempin, D. W., Goolsby, J. N. Anti-allergy composition and related method. US20087384654 (2008).
14. Muto, S., Itai, A. Antiallergic agents. US20107700655 (2010).
15. Knipping K, Van Esch Elisabeth CAM, Wijering SC, Van der heide S, Dubois AE, Garssen J. In vitro and in vivo anti-allergic effects of Arctium lappa L. Exp Biol Med 2008; 233: 1469-77.
16. Fabricant DS, Farnsworth NR. The value of plants used in traditional medicine for drug discovery. Environ Health Perspect 2001; 109: 69-75.
17. Jachak SM, Saklani A. Challenges and opportunities in drug discovery from plants. Curr Sci 2007; 92: 1251-1257.
18. Palpu, P., Rao, C. V., Rawat, A. K. S., Ojha, S. K., Reddy, G. D. Anti-allergic herbal formulation. US20087344739 (2008).
19. Calixto JB. Twenty-five years of research on medicinal plants in Latin America A personal view. J Ethnopharmacol 2005; 100: 131-4.
20. Newman DJ, Cragg, GM, Snader, KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003; 66: 1022-37.
21. Boldi AM. Libraries from natural product-like scaffolds. Curr Opin Chem Biol 2004; 8: 281-6.
22. Clardy J, Walsh C. Lessons from natural molecules. Nature 2004; 432: 729-837.
23. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov 2005; 4: 206-20.
24. Farnsworth NR, Akerele O, Bingel AS, Soejarto DD, Guo Z. Medicinal plants in therapy. WHO 1985; 63: 965-81.
25. Gupta SS. Prospects and perspectives of natural plant products in medicine. Indian J Pharmacol 1994; 26: 1-12.
26. Borchers AT, Hackman RM, Keen CL, Stern JS, Gershwin ME. Complementary medicine: A review of immunomodulatory effects of Chinese herbal medicines. Am J Clin Nutr 1997; 66: 1303-12.
27. Aravindaram K, Yang N-S. Anti-inflammatory plant natural products forcancer therapy. Planta Med 2010; 76: 1103-17.
28. Croteau R, Kutchan TM, Lewis NG. Natural Products (Secondary Metabolites). In: Buchanan B, Gruissem W, Jones R, Eds. Biochemistry and molecular biology of plants. The American society of plant physiologists. Waldorf, Waldorf, USA 2000; 1250-318.
29. Brossi, A. Antiinflammatory 2,3-didemethylcolchicine and additional derivatives. US4692463 (1987).
30. Novak, T. Skin care compositions having keratolytic and antiinflammatory activity. US4880630 (1989).
31. Chiou, G. C. Y., Chuang, C.-Y. Treatment of ocular inflamma-tion.US5041450 (1991).
32. Mizushima, Y., Hoshi, K., Igarashi, R., Ajioka, H., Yamamoto, N., Komuro, M., Kanehira, K., Inoue, M., Nishida, T., Terasawa, M., Arizono, K. 11-beta, 17-alpha, 21-trihydroxy-1, 4-pregnadiene-3, 20 21-[(E-E)-3,7, 11-trimethyl-2,6,10-dodecatrienoate]. US5278156 (1994).
33. Gerwick, W. H., Jacobs, R. S., Castenholz, R., Garcia-pichel, F., Grace, K. J. S., Proteau, P. J., Rossi J. Anti-flammatory method using indole alkaloids. US5461070 (1995).
34. Hennessey, R.K. Method for treating tendon or joint inflammation with papaverine HCL. US5576329 (1996).
35. Murayama, M. Aconitine compound and an antipyretic/analgesic/anti-inflammatory agent.US5770604 (1998).
36. Bombardelli, E. Colchicine and thiocolchicine derivatives with antiinflammatory and muscle relaxant activities.US5973204 (1999).
37. Pershadsingh, H. A., Avery, M. A. Flavonoid derivatives. US6028088 (2000).
38. Wright, A. E., Pomponi, S. A., Jacobs, R. S. Compounds and methods of use for treatment of neurogenic inflammation. US6291501 (2001).
39. Wu, T.-S., Kuo, S.-C., Teng, C.-M., Ko, F.-N. Method of preparing an extract potent in anti-inflammation and anti-platelet aggregation from Zingiber officinale and pharmaceutical compositions containing said extract. US6274177 (2001).
40. Newmark, T., Schulick, P. Herbal composition for reducing inflammation and methods of using same. US6264995 (2001).
41. Golding, B. T., Griffin, R. J., Quarterman, C. P., Slack, J. A., Williams, J. G. Analogues or derivatives of quercetin (pro-drugs). US6258840 (2001).
42. Manthey, J. A., Manthey, C. L., Montanari, A. Inhibition of cyto-kine production by polymethoxylated flavones. US6184246 (2001).
43. Han, Y.-B., Hong, E.-K., Chung, Y.-S., Kim, S.-J., Lee, K.-Y., Shin, Y.-L. Pharmaceutical composition comprising an aqueous extract of a mixture of anemarrhena rhizoma and phellodedron bark for analgesic and anti-inflammation.US6193977 (2001).
44. Hou, L. Herbal chinese joint complex. US6350476 (2002).
45. De Gregorio, C. Topical pharmaceutical compositions useful for the treatment of cutaneous of circulatory pathologies on inflammatory, immune, proliferative of degenerative basis. US6342255 (2002).
46. Kindness, G., Schumm B., Guilford, T. F. Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor. US6534540 (2003).
47. Nair, M. G., Wang, H., Strasburg, G. M., Booren, A. M., Gray, J. I. Method for inhibiting inflammation using bioflavonoids. US6576271 (2003).
48. Gebhardt, R., Vollmar, A. M., Manns, M. P., Bahr, M., Wagner, H., Buniatian, G. H. Use of Phyllanthus for treating chronic inflammatory and fibrotic processes. US6586015 (2003).
49. [L. M. Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto. US20040180102 (2004).
50. Krumhar, K. C. Method for treatment of inflammation and pain in mammals. US20056949260 (2005).
51. Chen, Y.-N. P., Lassota, P., Wood, A. W. Combinations comprising a selective cyclooxygenase-2 inhibitor.US20050043409 (2005).
52. Meng, C. Q., Ni, L., Sikorski, J. A., Hoong, L. K. 1,3-bis-(Substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders.US20067078431 (2006).
53. Raederstorff, D., Schwager, J., Spitzer, V., Weber, P. Novel nu-traceutical compositions and use thereof. US20060287256 (2006).
54. Scott, D. E. Application of dried nettle to the skin. US20060159786 (2006).
55. Kuhrts, E. H. Methods of administering anti-inflammatory cy-clooxygenase-2 selective inhibitors. US20070003646 (2007).
56. Vander Jagt, D. L., Deck, L. M. Substituted CIS- and trans-stilbenes as therapeutic agents. US20070249647 (2007).
57. Kwak, W.-J., Cho, Y.-B., Han, C.-K., Shin, H. J., Ryu, K. H., Yoo, H., Rhee, H.I. Extraction and purification method of active constituents from stem of Lonicera japonica thunb., its usage for anti-inflammatory and analgesic drug.US20087314644 (2008).
58. Kealey, K. S., Snyder, R. M., Romanczyk, L. J., Geyet, H. M., Myers, M. E., Whitacre, E. J., Schmitz, H.H. Treatment of inflammation. US20080188550 (2008).
59. Gokaraju, G. R., Gokaraju, R. R., Gottumukkala, V. S., Somepalli, V. Pharmaceutically active extracts of Vitex leucoxylon, a process of extracting the same and a method of treating diabetes and inflammatory diseases therewith. US20080199543 (2008).
60. Olalde Rangel, J. A. Arthritis phyto-nutraceutical synergistic composition. US20087416748 (2008).
61. Gokaraju, G. R., Gokaraju, R. R., Gottumukkala, V. S., Golakoti, T. Dietary supplement formulation for controlling inflammation and cancer. US20087455860 (2008).
62. Lockwood, S. F., Mason, P. R. Use of carotenoids and/or caro-tenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors. US20080293679 (2008).
63. Li, Y. Herbal compositions for prevention and treatment of rheumatic and inflammatory diseases and method of preparing the same. US20097553506 (2009).
64. Buchholz, H., Wirth, C., Carola, C., Alves Fontes, R. Flavonoid derivates.US20097588783 (2009).
65. Miyake, Y., Yoko, I. Anti-inflammatory agent. US20100120903 (2010).
66. Faergemann, J., Hedner, T., Sterner, O., Björk, L. Antimicrobial and antiiniflammatory composition. US20100331401 (2010).
67. Gokaraju, G. R., Gokaraju, R. R., Golakoti, T., Chirravuri, V. R., Alluri, V. K. R., Bhupathiraju, K. Use of Aphanamixis polystacha extracts or fractions against 5-lipoxygenase mediated diseases. US20100178288 (2010).
68. Hillwig, M. L. Anti-inflammatory and anti-HIV compositions and methods of use. US20107854946 (2010).
69. Theoharides, T. C. Anti-inflammatory compositions for treating multiple sclerosis. US20117906153 (2011).
70. Mumper, R. J., Dai, J., Gallicchio, V. S. Berry preparations and extracts. US20117964223 (2011).
71. Levine, W. Z., Nussbaum, G. Topical anti-inflammatory combination. US20110151032 (2011).
72. Jia, Q. Identification of free-B-Ring flavonoids as potent COX-2 inhibitors. US20117972632 (2011).
73. Calixto JB, Campos MM, Otuki MF, Santos ARS. Anti-inflammatory compounds of plant origin. Part II. Modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med 2004; 70: 93-103.
74. Kim HP, Kun HS, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci. 2004; 96: 229-245.
75. Nettis E, Colanardi MC, Ferrannini A, Tursi A. Antihistamines as important tools for regulating inflammation. Curr Med Chem-Anti-Inflammatory & Anti-Allergy Agents 2005; 4: 81-9.
76. 1)): anti-allergic activity of new phlorogluci-nol derivatives from Mallotus philippensis (Euphorbiaceae). Chem Pharm Bull 2002; 50: 1566-1659.
77. Sato, T., Matsumoto, H. Antiallergic agent. US4952564 (1990).
78. Shen T.Y., Goldstein, D., Gingrich, D. M. Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors.US5639782 (1990).
79. Steck, W., Hetherington, M. Oenothein medicaments. US6528490 (2003).
80. Yoshida, S. Preventive or therapeutic agent for pollen allergy, allergic rhinitis, atopic dermatitis, asthma or urticaria, or health food for prevention or improvement or reduction of symptoms thereof. US20046811796 (2004).
81. Frimman, B.K. Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract. US20118003688 (2011).
82. Borris RP. Natural products research: Perspectives from a major pharmaceutical company. J Ethnopharmacol 1996; 51: 29-38.
83. Turner DM. Natural product source material use in the pharmaceutical industry: The Glaxo experience. J Ethnopharmacol 1996; 51: 39-44.
84. Yoon J-H, Baek SJ. Molecular targets of dietary polyphenols with anti-inflammatory properties. Yonsei Med J 2005; 46: 585-96.
85. Thomasset SC, Berry DP, Garcea G, Marczylo T, Steward WP, Gescher AJ. Dietary polyphenolic phytochemicals - promising cancer chemopreventive agents in humans? A review of their clinical properties. Int J Cancer 2007; 120(3):451-8.
86. Russo GL. Ins and outs of dietary phytochemicals in cancer che-moprevention. Biochem Pharmacol 2007; 74: 533-44.